Sory I. Traore

Bracknell, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

A Cost-Effectiveness Analysis of Abemaciclib in Combination with Adjuvant Endocrine Therapy for HR+, HER2-, Node-Positive, High-Risk Early Breast Cancer.

A Cost-Effectiveness Analysis of Abemaciclib in Combination with Adjuvant Endocrine Therapy for HR+, HER2-, Node-Positive, High-Risk Early Breast Cancer.

Journal: Advances in therapy
Published: October 22, 2024

Bayesian survival extrapolation for cost-effectiveness analysis: a case study of RELAY for ramucirumab in combination with erlotinib in the treatment of non-small-cell lung cancer.

Bayesian survival extrapolation for cost-effectiveness analysis: a case study of RELAY for ramucirumab in combination with erlotinib in the treatment of non-small-cell lung cancer.

Journal: Journal of medical economics
Published: November 30, 2023

Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2-, node-positive, high-risk early breast cancer in Italy.

Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2-, node-positive, high-risk early breast cancer in Italy.

Journal: Global & regional health technology assessment
Published: January 12, 2023

Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis.

Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis.

Journal: Future oncology (London, England)
Published: February 21, 2022

Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US.

Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US.

Journal: Current medical research and opinion
Published: January 17, 2019

Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US.

Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US.

Journal: Journal of medical economics
Published: September 07, 2018

Erratum.

Erratum.

Journal: European heart journal. Quality of care & clinical outcomes
Published: October 19, 2017

Evolving quality standards for large-scale registries: the GARFIELD-AF experience.

Evolving quality standards for large-scale registries: the GARFIELD-AF experience.

Journal: European heart journal. Quality of care & clinical outcomes
Published: August 31, 2016

Epidemiological, clinical and therapeutic aspects of Ischemic stroke on atrial fibrillation associated with Rheumatic Valvular disease in the Department of Cardiology Of The Point G University Hospital - overview of 12 cases

Epidemiological, clinical and therapeutic aspects of Ischemic stroke on atrial fibrillation associated with Rheumatic Valvular disease in the Department of Cardiology Of The Point G University Hospital - overview of 12 cases

Journal: Le Mali medical
Published: January 01, 2013

Diagnosis and treatment of penile fracture in the Urology service of the Gabriel Touré Teaching Hospital

Diagnosis and treatment of penile fracture in the Urology service of the Gabriel Touré Teaching Hospital

Journal: Le Mali medical
Published: January 01, 2013
Showing 1-10 of 10

Last Updated: 09/26/2026